Kymera Therapeutics (KYMR) Stock: Buy, Sell, or Hold?
KYMR - Kymera Therapeutics, Inc. Common Stock
$110.85
-1.78 (-1.58%)
▼
5d:
+2.51%
30d:
-4.0%
90d:
+0.25%
BUY
MODERATE Confidence
Analysis Updated: Oct 22, 2026 12:00 AM ET
Earnings: Nov 03, 2026
10d
Get Alerted When KYMR Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: KYMR shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: KYMR shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: KYMR is currently trading at $110.85, which is considered fair relative to its 30-day fair value range of $107.76 to $116.00.
Technical Outlook: Technically, KYMR is in a uptrend. Immediate support is located at $104.39, while resistance sits at $115.81.
Market Sentiment: KYMR scores 66/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $139.35 (+25.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, KYMR is in a uptrend. Immediate support is located at $104.39, while resistance sits at $115.81.
Market Sentiment: KYMR scores 66/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $139.35 (+25.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$107.76 -
$116.00
Company Quality Score
58/100
(HOLD)
Options IV Signal
44th percentile
(NORMAL)
Volume Confirmation
HIGH
Confidence Score
83.3%
All Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Options fairly priced (IV 44th percentile)
- BULLISH: Strong technical setup (66/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 25.7% below Wall St target ($139.35)
- BULLISH: Bottoming setup score 66/100 — corrected, stabilizing, and turning up
Trading Range Analysis
30-Day Trading Range
$107.76 -
$116.00
Current vs Trading Range
FAIR
Expected Move (7 Days)
±$15.16
(13.7%)
Support & Resistance Levels
Support Level
$104.39
Resistance Level
$115.82
Current Trend
Uptrend
Technical data as of
Oct 22, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-21.75
Wall Street Target
$139.35
(+25.7%)
Revenue Growth (YoY)
466.4%
Profit Margin
-285.3%
Share & Embed Analysis
Last updated: October 23, 2026 3:47 AM ET
Data refreshes hourly during market hours. Next update: 4:47 AM
Data refreshes hourly during market hours. Next update: 4:47 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is KYMR showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
28 analysts |
$92 | 67 BUY |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
23 analysts |
$108 | 58 HOLD |
|
INCY
Incyte Corporation |
HOLD
28 analysts |
$130 | 77 BUY |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
22 analysts |
$283 | 49 HOLD |
|
DNTH
Dianthus Therapeutics In… |
STRONG BUY
17 analysts |
$141 | 56 HOLD |
Advanced KYMR Option Strategies
Professional options setups generated by AI based on today's KYMR price and gamma walls.
